BioDlink International Company Limited (1875.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$3.35 (-0.89%) as of
Key statistics
- Market cap
- 2.43B
- Forward P/E
- 40.73
- EPS (TTM)
- -0.260
- Dividend yield
- 0.00%
- 52-week range
- 1.700 – 5.870
- Beta
- -0.11
- Revenue (TTM)
- 504.52M
- Profit margin
- -32.30%
- Analyst target
- HK$4.47
- Volume
- 71.20k
About BioDlink International Company Limited
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. In addition, the company develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD). Further, it engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; license-out of self-developed biological drugs; and business development, investing, and marketing promotion activities. The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025. BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China. BioDlink International Company Limited operates as a subsidiary of WuXi XDC Cayman Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suzhou, China
- Employees
- 594
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.